This content is from: Premium Hedge Funds Loved This Investment in 2019 Managers hope 2020 is another huge year for health care and biopharma IPOs. By Stephen Taub December 30, 2019
This content is from: Premium These Hedge Fund-Backed Companies Are Going Public Market turmoil be damned — as many as four biopharma companies with hedge fund investors plan to IPO in the next few weeks. By Stephen Taub March 10, 2020
This content is from: Premium Biotech IPOs Are a Mixed Bag for Hedge Funds A recent spate of biotech company IPOs has yielded some early winners and losers. By Stephen Taub July 24, 2019
This content is from: Premium Horseman, Renaissance, Caxton Among Funds Posting Early March Gains In a market bloodbath, some funds stood out. By Stephen Taub March 12, 2020
This content is from: Premium Two Viking Portfolio Companies to Go Public This Week Three biopharmaceutical companies with hedge fund investors are poised for their public market debuts over the next few days. By Stephen Taub June 24, 2019
This content is from: Premium Renaissance Posts Middling Gains This Year Its institutional equities fund is trailing the markets, and its two other funds are treading water. By Michelle Celarier May 13, 2019
Sponsored Who’s on Your Equities Watch List? And, more importantly, how might they fit and function in your overall portfolio? This PM and his team relentlessly search for the answers. Sponsored by Mackenzie Investments April 01, 2020
